
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending CSL Behring’s ANDEMBRY (garadacimab) for …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

